Quantitative Mathematical Modeling of Clinical Brain Metastasis Dynamics in Non-small Cell Lung Cancer
Authors
Affiliations
Brain metastases (BMs) are associated with poor prognosis in non-small cell lung cancer (NSCLC), but are only visible when large enough. Therapeutic decisions such as whole brain radiation therapy would benefit from patient-specific predictions of radiologically undetectable BMs. Here, we propose a mathematical modeling approach and use it to analyze clinical data of BM from NSCLC. Primary tumor growth was best described by a gompertzian model for the pre-diagnosis history, followed by a tumor growth inhibition model during treatment. Growth parameters were estimated only from the size at diagnosis and histology, but predicted plausible individual estimates of the tumor age (2.1-5.3 years). Multiple metastatic models were further assessed from fitting either literature data of BM probability (n = 183 patients) or longitudinal measurements of visible BMs in two patients. Among the tested models, the one featuring dormancy was best able to describe the data. It predicted latency phases of 4.4-5.7 months and onset of BMs 14-19 months before diagnosis. This quantitative model paves the way for a computational tool of potential help during therapeutic management.
Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics.
Felfli M, Thinnes A, Jacques S, Liu Y, Iannessi A Front Immunol. 2025; 15:1470555.
PMID: 39759519 PMC: 11695367. DOI: 10.3389/fimmu.2024.1470555.
Radiation necrosis after radiation therapy treatment of brain metastases: A computational approach.
Ocana-Tienda B, Leon-Triana O, Perez-Beteta J, Jimenez-Sanchez J, Perez-Garcia V PLoS Comput Biol. 2024; 20(1):e1011400.
PMID: 38289964 PMC: 10857744. DOI: 10.1371/journal.pcbi.1011400.
Benzekry S, Schlicke P, Mogenet A, Greillier L, Tomasini P, Simon E Clin Exp Metastasis. 2023; 41(1):55-68.
PMID: 38117432 DOI: 10.1007/s10585-023-10245-3.
Circulating tumour cells for early detection of clinically relevant cancer.
Lawrence R, Watters M, Davies C, Pantel K, Lu Y Nat Rev Clin Oncol. 2023; 20(7):487-500.
PMID: 37268719 PMC: 10237083. DOI: 10.1038/s41571-023-00781-y.
Alvarez-Arenas A, Souleyreau W, Emanuelli A, Cooley L, Bernhard J, Bikfalvi A PLoS Comput Biol. 2022; 18(8):e1010444.
PMID: 36007057 PMC: 9451098. DOI: 10.1371/journal.pcbi.1010444.